Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer

• Published in: International journal of cancer Vol. 145; no. 6; pp. 1609 - 1624
• Main Authors: Liu, Yi‐Nan, Tsai, Meng‐Feng, Wu, Shang‐Gin, Chang, Tzu‐Hua, Tsai, Tzu‐Hsiu, Gow, Chien‐Hung, Chang, Yih‐Leong, Shih, Jin‐Yuan
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 15.09.2019; Wiley Subscription Services, Inc
• Subjects: acquired resistance; Adenocarcinoma - metabolism; Adenocarcinoma - pathology; Animals; AXL; Axl protein; Cancer; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; EGFR TKI; Enzyme inhibitors; Enzyme Inhibitors - pharmacology; Epidermal growth factor; Epidermal growth factor receptors; ErbB Receptors - antagonists & inhibitors; Extracellular signal-regulated kinase; Glycoproteins - metabolism; Heterografts; Humans; Intercellular Signaling Peptides and Proteins - metabolism; Kinases; Lung cancer; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Male; Medical research; Mice, Inbred BALB C; Mice, Nude; Non-small cell lung carcinoma; Patients; Phosphorylation; Proto-Oncogene Proteins - metabolism; Proto-Oncogene Proteins c-jun - metabolism; Receptor Protein-Tyrosine Kinases - metabolism; Signal transduction; Signal Transduction - drug effects; Stanniocalcin; stanniocalcin 2; Therapeutic applications; Tyrosine kinase inhibitors; lung cancer; stanniocalcin 2; EGFR TKI; AXL; acquired resistance
• ISSN: 0020-7136; 1097-0215; 1097-0215
• DOI: 10.1002/ijc.32487

Constitutive activation of the epidermal growth factor receptor (EGFR) signaling pathway is implicated in the initiation and progression of lung cancer. EGFR tyrosine kinase inhibitor (TKI)‐targeted therapy has become the standard treatment for nonsmall cell lung cancer (NSCLC) patients. However, ac...